Evaluation of the Tolerability and Efficacy of Adjuvant Treatment with Adipose Mesenchymal Stem/Stromal Cells in Dogs with Kidney Disease Secondary to Leishmaniosis
Authors:
- Mario Alberto GonzálezMGMario Alberto González
- Rafael Barrera-ChacónRBRafael Barrera-Chacón
- Joaquín Jiménez-FragosoJJJoaquín Jiménez-Fragoso
- Beatriz Macías-GarcíaBMBeatriz Macías-García
- Javier Fernández-CotrinaJFJavier Fernández-Cotrina
- María Gil-MolinoMGMaría Gil-Molino
- Nicolás Roberto RoblesNRNicolás Roberto Robles
- Francisco Eduardo Martín-CanoFMFrancisco Eduardo Martín-Cano
- Francisco Javier DuqueFrancisco Javier Duque
Open Access
Abstract
The tolerability and efficacy of treatment with allogeneic adipose-derived mesenchymal stem cells (aAMSCs) were evaluated in dogs with kidney disease secondary to canine leishmaniosis (CanL). In this non-blinded, single-center, 3-month study, twenty dogs received either conventional treatment (CT; n = 10) or conventional treatment plus an intravenous dose of aAMSCs (CT + aAMSCs; n = 10). Efficacy was assessed at days 0, 30, and 90 using plasma and urinary biomarkers. In both groups (CT, n = 6; CT + aAMSCs, n = 7), glomerular filtration rate was estimated by scintigraphy, and urinary proteomics was performed. No serious adverse events were observed, although two dogs experienced transient gastrointestinal events. No significant between-group differences occurred in renal parameters at time points. Intragroup analyses showed significant reductions in uNGAL/c in both groups and UPCR only in CT + aAMSCs. Longitudinal mixed-effects analyses revealed no significant group × time interactions for any of the evaluated variables. Urinary proteomics identified four protein entries with higher abundance in the CT + aAMSCs group at T90, although UMAP showed no separation between groups. A single intravenous aAMSCs dose was well tolerated but provided no renal benefits over conventional treatment. Further studies should evaluate alternative dosing protocols.Keywords
Funding Information
- European Commission (GR24094)
This publication has 60 references indexed in Scilit:
- Proteomic research on new urinary biomarkers of renal disease in canine leishmaniosis: Survival and monitoring response to treatmentResearch in Veterinary Science, 2023
- Adipose‐derived mesenchymal stem cells secrete extracellular vesicles: A potential cell‐free therapy for canine renal ischaemia‐reperfusion injuryVeterinary Medicine and Science, 2023
- Urinary proteome of dogs with renal disease secondary to leishmaniosisResearch in Veterinary Science, 2022
- Dimethyl sulfoxide-free cryopreservation solutions for hematopoietic stem cell graftsCytotherapy, 2022
- Urinary proteome and metabolome in dogs (Canis lupus familiaris): The effect of chronic kidney diseaseJournal of Proteomics, 2020
- Urinary peptidome analyses for the diagnosis of chronic kidney disease in dogsThe Veterinary Journal, 2019
- Adipose-derived stem cells ameliorate renal interstitial fibrosis through inhibition of EMT and inflammatory response via TGF-β1 signaling pathwayInternational Immunopharmacology, 2017
- Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: Clinical and laboratory outcomesThe Veterinary Journal, 2015
- Detection of Leishmania infantum kinetoplast minicircle DNA by Real Time PCR in hair of dogs with leishmaniosisVeterinary Parasitology, 2013
- Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long‐term serial adipose tissue–derived mesenchymal stem cell transplantationArthritis & Rheumatism, 2011